COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

New Funding Opportunity

Toward Translation of Nanotechnology Cancer Interventions (TTNCI), PAR-20-116

The National Cancer Institute has just posted a new funding opportunity entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)". TTNCI is meant to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

To be appropriate for this funding opportunity, the proposed nanotechnology approaches, materials, devices, and technologies should meet the following criteria:

  • The functional or active component(s) of devices or base materials either fabricated, assembled, or synthesized, must be at dimensions of 300 nm or less;
  • Materials used and/or proposed to be developed must be either synthetic or biologically-based materials that are engineered to provide novel properties or modified functions due to their controlled assembly or synthesis at the nanoscale.
  • Each proposed TTNCI project is expected to focus within one or more of three selected areas: 1) Combination therapy, 2) Immunotherapy, and 3) Imaging and Diagnostics.

This funding opportunity will NOT support projects that:

  • Propose nano-formulations utilizing traditional liposomes similar to those that have been approved by the FDA or are currently in clinical trials;
  • Involve discovery stage research on nanotechnology-based platforms with little to no prior evidence-based research;
  • Involve clinical trials or in vivo studies in human subjects;
  • Propose only the use of naturally-occurring materials (e.g., polysaccharides, proteins, viruses) that are not specifically engineered or modified for the intended function;
  • Focus on nanotechnology solutions for AIDS/HIV in the context of cancer.

Key Points:

Applications due dates: May 21, 2020; November 19, 2020; May 20, 2021; November 18, 2021

Award Amounts: Application budgets are limited to $475,000 in direct costs per year and need to reflect the actual needs of the proposed project

Project Period: The maximum project period is 4 years.


Please read the full application and eligibility details found here: